Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tendera, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tendera, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe

Michal Tendera*

Third Department of Cardiology, Silesian School of Medicine, Ziolowa Street 47, 40-635 Katowice, Poland

* Corresponding author. Tel: +48 32 353 9543; fax: +48 32 252 3930. E-mail address: mtendera{at}kardio3.katowice.pl

Chronic heart failure (CHF) is associated with a heavy burden of disease for patients and healthcare professionals. Quality of life and long-term prognosis for affected patients remain poor, and 5-year survival has been likened to that associated with some of the major malignancies. As a result of the ageing of the global population and the availability of effective treatments to prolong survival in patients with acute coronary syndromes, the incidence of CHF is increasing and the number of patients at risk of developing this condition is expected to grow. Despite the increasing prevalence of heart failure (HF), particularly in elderly populations, its exact incidence and prevalence remain largely unknown and probably underestimated due to a lack of accurate epidemiological data and difficulties associated with correct diagnosis. As a result, HF is associated with widespread undertreatment and the allocation of appropriate resources remains problematic. Numerous pharmacological therapies are available for the effective management of CHF, supported by a wealth of data from large scale, randomized clinical trials. Widespread adoption and implementation of evidence-based guidelines and treatment strategies are vital if survival is to be improved and patients are to receive optimal care for this devastating condition.

Key Words: Chronic heart failure • Epidemiology • Treatment • Europe


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
B. Maric, A. Kaan, A. Ignaszewski, and S. A. Lear
A systematic review of telemonitoring technologies in heart failure
Eur J Heart Fail, May 1, 2009; 11(5): 506 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. A. Konstam, P. A. Poole-Wilson, K. Dickstein, H. Drexler, S. J. Justice, M. Komajda, W. Malbecq, F. A. Martinez, J. D. Neaton, G. A.J. Riegger, et al.
Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor
Eur J Heart Fail, September 1, 2008; 10(9): 899 - 906.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.